1449598-06-4 Usage
Uses
Used in Pharmaceutical Industry:
RO6885247 is used as a potential therapeutic agent for the treatment of neurological disorders, specifically Alzheimer's disease, due to its ability to influence cognitive function and reduce the buildup of beta-amyloid plaques in the brain.
Used in Research and Development:
RO6885247 is used as a research compound to study its effects on the human trace amine-associated receptor 1 (TAAR1) and its potential role in modulating dopamine regulation and cognitive function, as well as its impact on the development of Alzheimer's disease.
Used in Drug Discovery:
RO6885247 is used as a lead compound in the development of new drugs targeting neurological disorders, with a focus on Alzheimer's disease, by exploring its interactions with TAAR1 and its potential to improve cognitive function and reduce beta-amyloid plaques.
Check Digit Verification of cas no
The CAS Registry Mumber 1449598-06-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,4,9,5,9 and 8 respectively; the second part has 2 digits, 0 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1449598-06:
(9*1)+(8*4)+(7*4)+(6*9)+(5*5)+(4*9)+(3*8)+(2*0)+(1*6)=214
214 % 10 = 4
So 1449598-06-4 is a valid CAS Registry Number.
1449598-06-4Relevant academic research and scientific papers
A PROCESS FOR THE PREPARATION OF 2-PYRAZOLO[1,5-A]PYRAZIN-2-YLPYRIDO[1,2-A]PYRIMIDIN-4-ONE
-
, (2017/12/09)
The present invention relates to a process for the preparation of 2-pyrazolo[1,5-a]pyrazin-2-ylpyrido[1,2-a]pyrimidin-4-one derivatives useful as pharmaceutically active compounds.
Specific Correction of Alternative Survival Motor Neuron 2 Splicing by Small Molecules: Discovery of a Potential Novel Medicine to Treat Spinal Muscular Atrophy
Ratni, Hasane,Karp, Gary M.,Weetall, Marla,Naryshkin, Nikolai A.,Paushkin, Sergey V.,Chen, Karen S.,McCarthy, Kathleen D.,Qi, Hongyan,Turpoff, Anthony,Woll, Matthew G.,Zhang, Xiaoyan,Zhang, Nanjing,Yang, Tianle,Dakka, Amal,Vazirani, Priya,Zhao, Xin,Pinard, Emmanuel,Green, Luke,David-Pierson, Pascale,Tuerck, Dietrich,Poirier, Agnes,Muster, Wolfgang,Kirchner, Stephan,Mueller, Lutz,Gerlach, Irene,Metzger, Friedrich
, p. 6086 - 6100 (2016/07/26)
Spinal muscular atrophy (SMA) is the leading genetic cause of infant and toddler mortality, and there is currently no approved therapy available. SMA is caused by mutation or deletion of the survival motor neuron 1 (SMN1) gene. These mutations or deletion
